hero-654791312-sized

Ensights

Science that is transforming lives and enabling the future

Rx-360 Audit Validates Entegris’ Life Sciences Filtration Manufacturing Supply Chain

All Posts

Rx-360 Audit Validates Entegris’ Life Sciences Filtration Manufacturing Supply Chain

We’re pleased to share that our Hangzhou, China facility has successfully completed an audit with the independent supply chain consortium, Rx-360.

With a focus on building strong partnerships between pharmaceutical manufacturers and suppliers, Rx-360 helps to ensure the integrity of supply chains through member-led working groups and their joint audit program. What makes this exciting is that many of Entegris’ customers who manufacture lifesaving therapeutics are also Rx-360 members. This provides easy ways to access the tools they need to qualify and validate their partners, suppliers, and customers to ensure patient safety.

Rx-360 Streamlines the Supplier Audit Process

Supplier audits are essential tools used to establish a safe and reliable supply chain. A supplier audit typically involves one or two auditors spending two or three days at a supplier’s site. During this time, they dig into all aspects of supplier’s manufacturing and supply chain operations, from processes and equipment to training and paperwork. These holistic audits are often a time-consuming and expensive activity for both parties involved. As such, audits are often a major barrier to adopting new suppliers.

Rx-360 conducts independent audits of suppliers to the biopharma industry, similar in scope and scrutiny to a pharmaceutical customer. These audit results are then made available to help alleviate the audit burden. This unlocks an easier transition to new materials and increased access to process expertise available from diverse suppliers.

Certifying Entegris as a Leading Pharmaceutical Supplier

The completion of the site audit with no major findings is a key validation of the new Entegris PharmsteriTM filter manufacturing supply chain. As a new entrant to the market, this important milestone demonstrates that our facility and quality systems are among the best in the industry.

Only the highest quality suppliers to the pharmaceutical market have Rx-360 reports available for examination. By making our audit report available to potential customers, we demonstrate that Entegris filtration solutions are among the highest performing and most reliable options available in a variety of markets. We also demonstrate that we can solve the full range of contamination control challenges.

The completion of this audit is a result of the extensive resources that have been deployed to establish the Hangzhou site as a premier life sciences manufacturing facility. Development of the global supply chain and preparation for the audit required extensive cross-functional support from the Entegris Hangzhou team as well as members from our Taiwanese and U.S. teams and demonstrates our continuing commitment to understanding and meeting customer needs globally.

Want to learn more? Visit our filtration resource page.

Related Posts

A Step-by-Step Guide to Cell Banking: Preserving the Precious Potential of Cells

Cell banking is the process of collecting, storing, and preserving cells for future use. It holds immense potential in the realm of medicine. From treating debilitating diseases to regenerating damaged tissues, cell banking offers a glimmer of hope for countless individuals. This guide will delve into the steps involved in the protection of these priceless resources.

Entegris and Qosina: Expediting Single-use Bioprocess Solutions Together

Have you ever needed to perform a test only to be held up by wait times for a single-use component? Perhaps you just need a small order of tubing or connectors, without everything that comes with a bulk order? We want to help customers get the right quantity of components when they need them. That’s why Entegris is proud to announce a new relationship with Qosina, a leading global supplier of OEM single-use components to the medical and pharmaceutical industries.

Is your Single-Use Solution Ready for Cell and Gene Therapy and Synthetic Gene Production?

The growth of the biomanufacturing industry has created a demand for new and high-performance fluid handling systems and technologies for the management and storage of cell and gene therapy intermediates and gene-based medicines. New modalities come with risks that don’t yet have good solutions.